[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 48 of about 48
1. Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K: Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol; 2005 Oct;58(10):1076-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
  • AIMS: To investigate the importance of gene amplification and EGFR (epidermal growth factor receptor) and HER2 protein expression during the progression of adenocarcinoma of the lung.
  • METHODS: EGFR and HER2 gene amplification was examined in atypical adenomatous hyperplasia (AAH), bronchioloalveolar carcinoma (BAC), and adenocarcinoma with mixed subtypes (MX) by chromogenic in situ hybridisation (CISH), and protein expression was examined by immunohistochemistry using paraffin wax embedded tissues.
  • Because EGFR and HER2 protein expression was frequently seen without gene amplification, other mechanisms apart from gene amplification may be associated with protein expression.
  • CONCLUSIONS: EGFR and HER2 gene amplification may be a late event and EGFR and HER2 protein expression may be associated with the development of adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Lung Neoplasms / genetics. Precancerous Conditions / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 May 6;86(9):1449-56 [11986780.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):339-45 [11786427.001]
  • [Cites] Lab Invest. 2002 Aug;82(8):1007-14 [12177239.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3046-53 [12374671.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):61-6 [12455054.001]
  • [Cites] Histopathology. 2003 Jun;42(6):575-9 [12786893.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):123-30 [12871775.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5238-43 [14614004.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):28-32 [14679115.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 [14734462.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):644-53 [15151204.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):893-901 [15208356.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1235-42 [15167937.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Pathol. 2000 Sep;192(1):26-31 [10951396.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1467-72 [11073807.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):480-3 [11304680.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2714-21 [11352964.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1089-95 [11378338.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):657-65 [12065780.001]
  • (PMID = 16189154.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromogenic Compounds; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC1770741
  •  go-up   go-down


2. Kikuchi E, Yamazaki K, Nakayama E, Sato S, Uenaka A, Yamada N, Oizumi S, Dosaka-Akita H, Nishimura M: Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun; 2008;8:13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.
  • XAGE-1b expression was examined immunohistochemically using USO9-13, an anti-XAGE-1b monoclonal antibody, in 121 NSCLCs (83 adenocarcinomas and 38 other histological types).
  • XAGE-1b expression was observed in 27 (32.5%) adenocarcinoma specimens.
  • In the other histological types, positive staining was observed in only 1 specimen.
  • Moreover, expression of XAGE-1b combined with down-regulated HLA class I expression correlated with poor survival (P = 0.01).
  • The density of cancer nest-infiltrating CD8+ T-cells in tumors expressing both XAGE-1b and HLA class I was higher than that in other groups.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / metabolism. Carcinoma, Non-Small-Cell Lung / immunology. Histocompatibility Antigens Class I / immunology. Lung Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Pathol. 1999 Jan;187(2):191-9 [10365094.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8055-62 [16299236.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):337-43 [17066423.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):835-40 [17332921.001]
  • [Cites] Cancer Immun. 2007;7:5 [17335148.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1424-30 [17645781.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):625-30 [10684854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10290-5 [11517302.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):195-204 [11774264.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):441-50 [12479262.001]
  • [Cites] Cancer Immun. 2002 Sep 19;2:12 [12747757.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):558-63 [14696120.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Am J Clin Pathol. 1982 Feb;77(2):123-36 [7064914.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1445-8 [10197611.001]
  • [Cites] Immunity. 1999 Mar;10(3):281-7 [10204484.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5496-503 [16061866.001]
  • (PMID = 18752338.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class I; 0 / XAGE1A protein, human
  • [Other-IDs] NLM/ PMC2935781
  •  go-up   go-down


3. Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, West H: Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol; 2006 Nov;1(9 Suppl):S32-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
  • INTRODUCTION: Bronchioloalveolar carcinoma (BAC) is a subtype of adenocarcinoma of the lung with unique pathological, clinical, and molecular characteristics.
  • METHODS: This consensus conference group reviewed studies performed specifically in BAC and data from patients with BAC who were included in clinical trials of all non-small-cell lung cancer (NSCLC) subtypes.
  • Patients with BAC are routinely treated with drugs and regimens appropriate for patients with all subtypes of adenocarcinoma of the lung; four studies have been performed specifically in this disease.
  • CONCLUSIONS: There is insufficient evidence to confirm or refute the assertion that the sensitivity of BAC to chemotherapy is different from that of other lung cancer histologic types.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409999.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  • [Number-of-references] 30
  •  go-up   go-down


Advertisement
4. Cicenas S, Zaliene A, Atkocius V: [Treatment outcome of locally advanced stage IIIA/B lung cancer]. Medicina (Kaunas); 2009;45(6):452-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to morphology, there were 219 (72%) patients with squamous cell lung cancer, 80 (26.3%) with adenocarcinoma, and 5 (1.7%) patients with large cell carcinoma.
  • Surgery was performed in 145 patients: 84 (57.9%) patients underwent lung resection (T3-4N0-1M0), 51 (35.2%) patients - thoracotomy, and 10 (6.7%) patients - other palliative thoracic procedures (mediastinotomy, pleurectomy, mediastinoscopy).
  • Better treatment outcomes, i.e. longer survival, can be achieved when a combination of three treatment types - surgery, chemotherapy, and radiation therapy - is applied to patients with stage IIIA or IIIB non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Lung / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Radiotherapy Dosage. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605965.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • Additional markers may improve on its individual performance if they increase sensitivity and specificity and are less sensitive to other gynecologic conditions.
  • EXPERIMENTAL DESIGN: We here validate the performance of hK11 on an independent data set and further characterize its behavior in multiple types of controls.
  • We also investigate its behavior when combined with CA 125 to form a composite marker. hK11 had not previously been evaluated on these serum samples.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


6. Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL: Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res; 2006 Oct 1;66(19):9617-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a syngeneic colon carcinoma tumor model, treatment of the tumor-bearing mice with an agonistic antibody against murine LT beta R caused increased lymphocyte infiltration and necrosis of the tumor.
  • A pattern of differential gene expression predictive of cellular and xenograft response to LT beta R activation was identified in a panel of colon carcinoma cell lines and when applied to a panel of clinical colorectal tumor samples indicated 35% likelihood a tumor response to CBE11.
  • Consistent with this estimate, CBE11 decreased tumor size and/or improved long-term animal survival with two of six independent orthotopic xenografts prepared from surgical colorectal carcinoma samples.
  • Targeting of LT beta R with agonistic mAbs offers a novel approach to the treatment of colorectal and potentially other types of cancers.
  • [MeSH-major] Adenocarcinoma / therapy. Antibodies, Monoclonal / therapeutic use. Colonic Neoplasms / therapy. Lymphotoxin beta Receptor / agonists. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Animals. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cell Line, Tumor. Combined Modality Therapy. Drug Synergism. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunoglobulin G / immunology. Immunoglobulin G / therapeutic use. Immunoglobulin M / immunology. Immunoglobulin M / therapeutic use. Lymphocytes, Tumor-Infiltrating / immunology. Mice. Mice, Inbred BALB C. Mice, Nude. Random Allocation. Recombinant Fusion Proteins / immunology. Recombinant Fusion Proteins / therapeutic use. Single-Blind Method. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018619.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Ltbr protein, mouse; 0 / Lymphotoxin beta Receptor; 0 / Recombinant Fusion Proteins; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Pectasides D, Pectasides E, Psyrri A, Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist; 2006 Nov-Dec;11(10):1089-94
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment issues in clear cell carcinoma of the ovary: a different entity?
  • BACKGROUND: Ovarian clear cell carcinoma (OCCC) is a distinct histopathologic subtype of epithelial ovarian cancer (EOC) with an incidence of <5% of all ovarian malignancies.
  • Recurrences are more frequent with this entity than with other types of EOC.
  • Despite their aggressive clinical course, OCCCs are still treated similarly to the other EOCs at the present time, because the rarity of these tumors prevents the conduction of randomized studies.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110628.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


8. Rapa I, Volante M, Cappia S, Rosas R, Scagliotti GV, Papotti M: Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. Am J Clin Pathol; 2006 Jun;125(6):847-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth.
  • Lung bronchioalveolar carcinomas (BACs) are noninvasive tumors showing lepidic growth and excellent prognosis, whereas all the other variants of adenocarcinoma are invasive tumors with a worse prognosis.
  • The identification of minimal invasive foci in adenocarcinoma, therefore, is of prognostic relevance.
  • A series of 68 pulmonary tumors, including 40 acinar/papillary adenocarcinomas, 18 adenocarcinomas of the mixed subtype, and 10 BACs was tested by immunohistochemical analysis for cathepsin K expression, a proteinase involved in bone and extracellular matrix remodeling.
  • Our findings suggest pathogenetic implications of cathepsin K in the mechanisms of tumor invasiveness in lung carcinoma; in addition, cathepsin K immunodetection may be a valuable adjunct in the correct classification of pulmonary adenocarcinomas, especially in small sclerosing BACs and mixed adenocarcinoma subtypes with minimal infiltrative growth.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma, Bronchiolo-Alveolar / enzymology. Cathepsins / metabolism. Lung Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690483.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
  •  go-up   go-down


9. Awaya H, Takeshima Y, Amatya VJ, Ishida H, Yamasaki M, Kohno N, Inai K: Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. Pathol Int; 2005 Jan;55(1):14-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma.
  • The aim of the present study was to determine the association of loss of membranous expression of epithelial (E)-cadherin and beta-catenin with the progression of pulmonary adenocarcinoma.
  • The expression of E-cadherin and beta-catenin was examined in 154 cases of pulmonary adenocarcinoma, including 49 cases of atypical adenomatous hyperplasia (AAH), 40 cases of bronchioloalveolar carcinoma (BAC), 42 cases of BAC-dominant type of adenocarcinoma with mixed subtypes (early MX) and 23 cases of BAC-recessive type of adenocarcinoma with mixed subtypes (overt MX), by immunohistochemistry.
  • Loss of expression of E-cadherin and beta-catenin may play an important role in the progression of pulmonary adenocarcinoma, and these events occur before structural destruction of the alveolar wall by invasion of carcinoma cell.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cadherins / biosynthesis. Cytoskeletal Proteins / biosynthesis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Trans-Activators / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660698.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


10. Matsuoka T, Fukamitsu G, Onoda M, Uesugi N, Kawano K, Katou T: [Synchronous multiple lung cancer including a lesion with a thin-walled cavity; report of a case]. Kyobu Geka; 2010 Feb;63(2):164-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 79-year-old woman underwent video-assisted thoracic surgery (VATS)-left S6 segmentectomy for left lung cancer (papillary adenocarcinoma, pT1N0M0, stage IA), and were followed-up at our hospital.
  • CT-guided biopsy revealed well differentiated adenocarcinoma VATS-right upper lobectomy was performed and both lesions were diagnosed as "adenocarcinoma with mixed subtypes (BAC : acinar type), synchronous multiple lung cancer one of which formed thin-walled cavity" histopathologically.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141088.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Fujita A, Kameda Y, Goya T: Clinicopathology of stromal invasion in lung adenocarcinoma. Pathol Int; 2009 Jan;59(1):1-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathology of stromal invasion in lung adenocarcinoma.
  • In the World Health Organization classification, lung adenocarcinoma with mixed subtypes is defined as invasive carcinoma with evidence of vascular, pleural, or stromal invasion.
  • A total of 157 peripheral pure bronchioloalveolar carcinoma (BAC) or lung adenocarcinoma with mixed BAC and others were reviewed.
  • Survival of patients with adenocarcinoma without DAF (n = 41) was 100%.
  • Even when adenocarcinoma involved DAF and lacked EAAI (n = 21), survival was 100%.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121086.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


12. Jian Z, Tomizawa Y, Yanagitani N, Iijima H, Sano T, Nakajima T: Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes. Pathol Int; 2005 Oct;55(10):619-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes.
  • To clarify the clinicopathological nature of papillary adenocarcinoma (PA) of the lung, 20 cases of PA were collected consecutively from resected adenocarcinoma of the lung, studied immunohistochemically and, using molecular techniques, compared with bronchioloalveolar carcinoma (BAC).
  • Morphologically, PA was divided into two subtypes according to the presence of residual alveolar structures, detected by elastica van Gieson stain.
  • One of these subtypes was closely related to the morphology of BAC and might be diagnosed as adenocarcinoma with mixed subtypes.
  • The other PA subtype was composed of tall columnar cells and grew compressively, which was similar to type F adenocarcinoma previously reported by Noguchi et al.
  • Immunohistochemical studies using lung tissue-specific antigens, progression markers and tumor suppressor products found that PA seemed a more advanced adenocarcinoma than BAC, but no differences were observed among PA subtypes.
  • Molecular biological analysis using three microsatellite markers at chromosome 3p revealed more frequent loss of heterozygosity in PA than BAC, with no differences among PA subtypes.
  • These findings suggest that PA is a more advanced adenocarcinoma subtype than BAC.
  • Further investigations are needed to clarify true PA as clinicopathologically and biologically independent from other histological subtypes of adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185291.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


13. Goto T, Maeshima A, Oyamada Y, Wakaki M, Hamaguchi R, Kato R: A surgical case of quadruple lung cancer. Ann Thorac Cardiovasc Surg; 2010 Oct;16(5):345-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because adenocarcinoma was diagnosed by intraoperative frozen sectioning, a left lower lobectomy and lymph node dissection were performed.
  • The pathological diagnosis was adenocarcinoma with mixed subtypes (AMS, pT1N0M0).
  • Histologically, the middle-lobe tumor was solid adenocarcinoma with mucin (pT1N0M0).
  • Although no gross tumor could be identified in the upper lobe, histological examination revealed nonmucinous bronchioloalveolar carcinoma (pT1N0M0).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21030922.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Ishizuka T, Endo S, Tsubochi H, Nakano T, Miwa C, Watanabe K, Koyama S, Nokubi M, Sohara Y: [Mucinous bronchiolo-alveolar cell carcinoma with marked serum elevation of CA19-9: report of a case]. Kyobu Geka; 2009 Jun;62(6):509-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous bronchiolo-alveolar cell carcinoma with marked serum elevation of CA19-9: report of a case].
  • The pathologic study obtained by a transbronchial tumor biopsy revealed a mucinous adenocarcinoma The patient underwent video-assisted thoracoscopic right middle and lower bi-lobectomies with nodal sampling.
  • Postoperative course was uneventful Pathologic study revealed an adenocarcinoma with mixed subtypes, predominantly composed of mucinous bronchiolo-alveolar cell carcinoma (BAC).
  • Immunohistochemical study showed CA19-9 positivity in the apical surface of some tumor cells and diffuse patterns of other tumor cells.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522216.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


15. Makimoto Y, Nabeshima K, Iwasaki H, Miyoshi T, Enatsu S, Shiraishi T, Iwasaki A, Shirakusa T, Kikuchi M: Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (&lt;/=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology; 2005 Jun;46(6):677-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours).
  • AIMS: A micropapillary pattern (MPP) in lung adenocarcinoma, characterized by papillary structures with epithelial tufts lacking a central fibrovascular core, has been reported to be a new pathological marker of poor prognosis.
  • A new histological classification of small lung adenocarcinoma proposed by Noguchi et al. has been found to be useful since it has defined surgically curable bronchioloalveolar carcinoma (BAC)-type tumours (Noguchi's type A and B) based on the absence of active fibroblastic proliferation.
  • However, BAC-type tumours with active fibroblastic proliferation (Noguchi's type C), which is adenocarcinoma with mixed subtypes including BAC and invasive carcinoma in the new World Health Organization (WHO) classification, account for most of the small adenocarcinomas and represent a heterogeneous group ranging from minimal to overtly invasive cancer with variable prognoses.
  • Therefore, in this study the aim was to investigate whether MPP can be an additional histological marker(s) to subclassify this heterogeneous group in small lung adenocarcinoma.
  • The 5-year survival rates of BAC (Noguchi's type A and B) (n=14), mixed BAC and invasive adenocarcinoma (Noguchi's type C) (n=85) and invasive adenocarcinoma (Noguchi's type D and F) (n=23) were 100%, 68% and 36%, respectively.
  • In patients with mixed BAC and invasive adenocarcinoma (Noguchi's type C tumours), the 5-year survival of the MPP-positive group (n=51) was 54%, significantly lower than that of the MPP-negative group (n=23) of 100% (P=0.02).
  • CONCLUSIONS: MPP is a simple and distinct pathological marker to subclassify tumours with a significantly poor prognosis within small (</=20 mm) mixed BAC and invasive adenocarcinoma (Noguchi's type C tumours).
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910599.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


16. Bell D, Luna MA: Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm. Ann Diagn Pathol; 2009 Jun;13(3):201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm.
  • Carcinomas arising in or from the epithelial component of preexisting parotid Warthin tumors (WTs) are rare; the other histologic types of carcinoma found to arise from WTs are adenocarcinoma not otherwise specified, undifferentiated, mucoepidermoid, squamous cell, and oncocytic.
  • We have designated this neoplasm "Warthin adenocarcinoma" (WA).
  • Anderson Cancer Center for cases of malignant WT and salivary adenocarcinoma not otherwise specified diagnosed from January 1, 1985, through December 31, 2006, and evaluated patients' medical records and pathologic material.
  • A residual WT with transition to carcinoma was identified in both cases.
  • Warthin adenocarcinoma is a unique salivary gland carcinoma representing the malignant epithelial counterpart of WT.
  • [MeSH-major] Adenocarcinoma / pathology. Adenolymphoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Oral Surgical Procedures. Radiotherapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433301.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kiprian D: [Strategy of combined treatment in patient with cancer of paranasal sinuses]. Otolaryngol Pol; 2007;61(4):527-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy of combined treatment in patient with cancer of paranasal sinuses].
  • Other types of cancer in this region are adenocarcinoma (about 30%), carcinoma adenoides cysticum or neoplasms such as rhabdosarcoma, chondrosarcoma, lymphoma or melanoma malignum.
  • The radiation treatment combined with chemotherapy is applied in cases of not radical surgery in the region of ethmoides sinuses.
  • [MeSH-minor] Combined Modality Therapy. Humans. Incidence. Neoplasm Staging. Radiotherapy, Conformal. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260245.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 5
  •  go-up   go-down


18. Kasamatsu A, Endo Y, Uzawa K, Nakashima D, Koike H, Hashitani S, Numata T, Urade M, Tanzawa H: Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int J Biochem Cell Biol; 2005 Sep;37(9):1869-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses.
  • Adenoid cystic carcinoma (ACC) of the salivary gland often has a variable clinical course with a poor prognosis.
  • To investigate DNA copy number aberrations associated with ACCs, we compared comparative genome hybridization data from ACCs (n = 6) with other types of salivary gland tumors such as adenocarcinomas (n = 3) and pleomorphic adenomas (n = 6).
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Gene Expression Profiling. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908262.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  •  go-up   go-down


19. Zhao ZL, Song N, Huang QY, Liu YP, Zhao HR: [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases]. Ai Zheng; 2007 Feb;26(2):183-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features of lung pleomorphic (spindle/giant cell) carcinoma--a report of 17 cases].
  • BACKGROUND & OBJECTIVE: Lung pleomorphic (spindle/giant cell) carcinoma is a rare epithelial malignant tumor.
  • METHODS: Clinicopathologic records of 17 patients with lung pleomorphic (spindle/giant cell) carcinoma were reviewed and compared with those of the patients with other histopathologic types of lung cancer treated in the same period.
  • Of the 17 cases of lung pleomorphic (spindle/giant cell) carcinoma, 2 were lung exclusive spindle cell carcinoma, 5 were lung carcinoma with spindle cells (combined with one kind of epithelial components, such as squamous cell carcinoma in 3 cases, adenocarcinoma in 1 case, and large cell carcinoma in 1 case), 10 were lung carcinoma with giant cell carcinoma (combined with one kind of epithelial components in 5 cases, two kinds in another 5 cases).
  • The median survival time was significantly shorter in lung pleomorphic (spindle/giant cell) carcinoma patients than in lung squamous cell carcinoma patients (36 months vs. 61 months, P=0.027), and was also significantly longer in patients with carcinoma containing spindle cells (including spindle cell carcinoma) than in patients with carcinoma containing giant cells (64 months vs. 18 months,P=0.026).
  • Lymph node metastasis and carcinoma containing giant cells were poor prognostic factors of lung pleomorphic (spindle/giant cell) carcinoma.
  • CONCLUSION: Lung carcinoma containing giant cells has multiple cells components, and has worse prognosis than lung carcinoma containing spindle cells and spindle cells carcinoma do.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298750.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Paduch R, Kandefer-Szerszeń M, Piersiak T: The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs. Oncol Res; 2010;18(9):419-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
  • We analyzed the levels of reactive oxygen species (ROS), nitric oxide (NO), and cachexia-mediated cytokines (IL-1beta, IL-6, TNF-alpha) in cocultures of human colon carcinoma spheroids prepared with cells derived from tumors of different grades with human normal colon epithelial and myofibroblast cells and normal endothelial cells.
  • We also analyzed the influence of standard chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) combined with camptothecin (CPT-11) (IFL regimen with drug concentrations adjusted to in vitro conditions) on these parameters.
  • The results indicated that adhesion of colon carcinoma spheroids to colon epithelium and myofibroblast monolayers induced O2- anion production but decreased NO levels compared to the sum of the radicals released by monocultures of the two types of cells.
  • Coculture of colon carcinoma spheroids with endothelium was an exception to this rule, as only HT29 cells decreased NO production.
  • However, the levels of released ROS and NO were dependent on the stage of colon carcinoma that the cells were derived from.
  • On the other hand, high level of NO seems to facilitate tumor cell interactions with the endothelium and metastasis as NO production was the highest in a monoculture of HUVEC and remained at high levels in cocultures of colon cancer cells with HUVEC.
  • Among the proinflammatory cytokines, only IL-6 seems to significantly influence colon carcinoma development and metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Cytokines / metabolism. Nitric Oxide / metabolism. Reactive Oxygen Species / metabolism. Spheroids, Cellular / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Camptothecin / administration & dosage. Coculture Techniques. Colon / drug effects. Colon / metabolism. Colon / pathology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Enzyme-Linked Immunosorbent Assay. Fibroblasts / drug effects. Fibroblasts / metabolism. Fibroblasts / pathology. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Metastasis

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524400.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Reactive Oxygen Species; 31C4KY9ESH / Nitric Oxide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Tsuta K, Ishii G, Nitadori J, Murata Y, Kodama T, Nagai K, Ochiai A: Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol; 2006 May;209(1):78-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin.
  • The latest World Health Organization (WHO) classification divides adenocarcinoma mainly into adenocarcinoma mixed subtypes, acinar adenocarcinoma, papillary adenocarcinoma, bronchioloalveolar carcinoma, and solid adenocarcinoma with mucin production, and it mentions several variants, including fetal adenocarcinoma, mucinous ("colloid") adenocarcinoma, mucinous cystadenocarcinoma, signet-ring adenocarcinoma, and clear cell adenocarcinoma.
  • In general, the mucin-producing adenocarcinoma of the lung comprises signet-ring cell carcinoma (SRCC), solid adenocarcinoma with mucin production (SA), and mucinous bronchioloalveolar carcinoma (m-BAC), mucinous ("colloid") adenocarcinomas and/or mucinous cystadenocarcinoma, and mucoepidermoid carcinoma.
  • [MeSH-major] Adenocarcinoma / immunology. Lung Neoplasms / immunology. Mucins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / immunology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / immunology. Carcinoma, Signet Ring Cell / metabolism. Humans. Immunoenzyme Techniques. Immunophenotyping. Protein Array Analysis / methods

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16463270.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins; 0 / Neoplasm Proteins
  •  go-up   go-down


22. Gamal G, Sano T, Sakurai S, Kawashima O, Sugano M, Nakajima T: Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis. Pathol Int; 2007 Dec;57(12):765-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistopathological re-evaluation of adenocarcinoma of the lung with mixed subtypes using a tissue microarray technique and hierarchical clustering analysis.
  • To re-evaluate adenocarcinoma, mixed subtypes (ADMIX) of the lung, a total of 201 cases were classified into three main subgroups according to the most differentiated histological growth pattern; namely bronchioloalveolar carcinoma (BAC)-mixed, which was the most predominant (73.1%), papillary (PAP)-mixed (21.9%), and acinar-mixed (5%).
  • The PAP-mixed was significantly male predominant and had more progressed clinicopathological features.
  • Hierarchical clustering analysis was separately applied to the immunohistochemical results of ADMIX and ADMIX subgroups, and it was found that most acinar-mixed cases were placed in a separate cluster, while the BAC-mixed and PAP-mixed failed to form significant independent clusters.
  • The antibody clustering profile for the acinar-mixed was clearly different from that for the BAC-mixed or PAP-mixed, but the PAP-mixed shared a dendrogram profile with the other two subgroups.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988277.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Luo DL, Liu YH, Zhuang HG, Liao RQ, Luo XL, Xu FP, Zhang F: [Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Nov;37(11):737-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma].
  • OBJECTIVE: Further investigation on the incidence and clinicopathologic features of bronchioloalveolar carcinomas (BAC) including:.
  • (1) BAC of strictly defined, (2) adenocarcinoma with bronchioloalveolar features, (3) other different histologic subtypes of lung adenocarcinomas.
  • METHODS: Surgical specimens from 348 lung adenocarcinoma patients admitted in that hospital between 1998 - 2005 were included.
  • RESULTS: The resected lung adenocarcinomas consisted of different histologic subtypes.
  • The most frequent one was adenocarcinoma of mixed subtypes (78.2%, 272/348), followed by the acinar type (8.1%, 28/348), the papillary type (4.0%, 14/348), the BAC (3.7%, 13/348), the mucinous (colloid) type (3.4%, 12/348) and the solid types (2.3%, 8/348).
  • The fetal adenocarcinoma was the least component detected.
  • CONCLUSIONS: Since patients with strictly defined (simple) BAC, BWFI, and AWBF have their own distinct clinicopathologic features and prognosis respectively, they should be strictly distinguished from other types of pulmonary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Kaplan-Meier Estimate. Lung Neoplasms / pathology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094707.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M: Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Clin Transl Oncol; 2006 Oct;8(10):742-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology types were: adenocarcinoma in 8 patients (38%), large cell carcinoma in 1 patients (5%) and squamous cell carcinoma in 12 patients (57%).
  • Our results are similar with other sequential regimens and did not represent a significant improvement in the treatment of this disease.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Taxoids / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074673.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


25. Nakanuma Y, Sasaki M, Ikeda H, Sato Y, Zen Y, Kosaka K, Harada K: Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol Res; 2008 Apr;38(4):325-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intrahepatic CCs can be divided into the perihilar and peripheral types.
  • Peripheral CCs present grossly as a mass forming tumor, and histologically as an adenocarcinoma of varying shapes and phenotypes.
  • This type shows: (i) grossly, a blurred border; and (ii) histologically, carcinoma cells replacing the adjoining hepatocytes at the border of the tumor.
  • The other peripheral CC (duct type) includes ordinary adenocarcinoma with well to moderately differentiated tubular and micropapillary patterns and is negative for NCAM but positive for mucin.
  • Interestingly, CC components of combined hepatocellular CC share the features of ductular CC, suggesting that hepatic progenitor cells may be involved in the tumorigenesis of ductular CC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18093122.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev; 2008 Dec;34(8):693-700
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest histologic subtypes encountered were adenocarcinoma (N=34) or undifferentiated carcinoma (N=12).
  • The liver was the only metastatic site in 38% of patients, while it was accompanied with other metastatic sites in 62% (the commonest: lung, bone and lymph nodes).
  • CONCLUSIONS: Patients with liver metastases from CUP are resistant to conventional types of treatment and carry a poor prognosis.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584969.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 22
  •  go-up   go-down


27. Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J: The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol; 2010 Mar;116(3):301-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 427 patients (median age: 55 years), 69% had stage I disease, 30% had clear cell, 25% endometrioid, 23% serous, 7% mucinous, and 15% had other cell types.
  • Nevertheless, a test of homogeneity did not show a difference in treatment effects across cell types (p=0.285).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19945740.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Luo LM, Huang HF, Pan LY, Shen K, Wu M, Xu L: [Clinical analysis of 42 cases of primary malignant tumor in vagina]. Zhonghua Fu Chan Ke Za Zhi; 2008 Dec;43(12):923-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen cases were squamous carcinoma, 13 cases were malignant melanoma, 8 cases were adenocarcinoma, 3 cases were yolk sac tumor and 5 cases were other types.
  • The majority of patients were treated with surgery combined with radiotherapy and chemotherapy.
  • The 2-year survival rate of patients with squamous carcinoma was 46.8%, malignant melanoma 72.9%, adenocarcinoma 20.0% and patients with yolk sac tumor were all alive tumor-free after 6 - 10 years' follow up.
  • As to malignant melanoma, radical surgery combined with chemotherapy and immunotherapy produce good effects.
  • As to other types, more treatment experiences are needed.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Infant. Melanoma / mortality. Melanoma / pathology. Melanoma / surgery. Melanoma / therapy. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Vagina / pathology. Vagina / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134332.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This cancer was diagnosed at a slightly advanced stage and with more cases positive for lymph node metastases than other subtypes.
  • Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • Apocrine carcinoma was also found very frequently in the TN group.
  • Selection of chemotherapy was not based on receptor subtypes, but was determined by the degree of tumor progression.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


30. Deme D, Ragán M, Kalmár K, Kovács L, Varga E, Varga T, Rakonczai E: [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case]. Magy Onkol; 2010 Dec;54(4):351-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basically two types of DIC are distinguished:.
  • Chronic DIC related to metastatic neoplasia is caused by pancreatic, gastric or prostatic carcinoma in most of the cases.
  • In other words, chronic DIC is developed in one of eight patients with prostate cancer.
  • DIC is considered as a poor prognostic factor in prostatic carcinoma.
  • Elevated prostate-specific antigen (PSA) (109.6 ng/mL) suggested prostatic carcinoma.
  • Prostate biopsy revealed adenocarcinoma (Gleason: 4+4 for left lobe and 3+3 for right lobe).
  • Combined androgen blockade (CAB) was started.
  • [MeSH-major] Acute Kidney Injury / etiology. Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / therapy. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / drug therapy


31. Tsunoda-Shimizu H, Hayashi N, Hamaoka T, Kawasaki T, Tsugawa K, Yagata H, Kikuchi M, Suzuki K, Nakamura S: Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging. Breast Cancer; 2008;15(2):133-40
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One is a type of invasive carcinoma that tends to grow along the mammary ducts (type A1), another is a type of expansively growing invasive carcinoma that is relatively well-defined (type A2), a third is a type of irregularly shaped mass that retracts surrounding tissue (type A3), and the fourth is a mixed type.
  • Thus, the effects of neoadjuvant chemotherapy on carcinomas of the four types were compared on the basis of image and pathological findings.
  • Effects of neoadjuvant chemotherapy were classified into three categories of enlarged mass, pCR, and other, with the latter indicating no change or shrinkage.
  • RESULTS: Of the 186 total cases, 72 were classified as type A1, 31 as type A2, 52 as type A3, and 31 as a mixed type.
  • Dividing cases into type A2 and other types and looking at the proportion of cases of an enlarged mass thus indicated a significantly higher tendency. pCR was achieved in 6 of 31 cases with type A2 (19.4%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / classification. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Diagnostic Imaging. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Middle Aged. Prognosis. Retrospective Studies. Stereoisomerism. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288570.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


32. Santibañez M, Vioque J, Alguacil J, Barber X, García de la Hera M, Kauppinen T, PANESOES Study Group: Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain. Occup Environ Med; 2008 Nov;65(11):774-81
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occupational, sociodemographic and lifestyle information was collected from 185 newly diagnosed male oesophageal cancer patients (147 squamous cell, 38 adenocarcinoma) and 285 frequency matched controls.
  • RESULTS: For the squamous cell variety, statistically significant associations were found for waiters and bartenders (OR 8.18, 95% CI 1.98 to 33.75) and miners, shotfirers, stone cutters and carvers (OR 10.78, 95% CI 1.24 to 93.7) in relation to other occupations.
  • For the adenocarcinoma variety, statistically significant associations were observed for carpenters and joiners (OR 9.69), animal producers and related workers (OR 5.61) and building and related electricians (OR 8.26), although these observations were based on a low number of cases.
  • Regarding specific exposures, the study found a statistically significant increased risk of squamous cell carcinoma for ionising radiation, and of adenocarcinoma for high exposure to volatile sulphur compounds (OR 3.12) and lead (OR 5.30).
  • For all histological types of OC combined, a three-fold increase in risk was found with a significant trend for asbestos exposure (OR 3.46, 95% CI 0.99 to 12.10).
  • CONCLUSIONS: The data suggest that some occupational exposures may specifically increase the risk of oesophageal squamous cell carcinoma or adenocarcinoma, while other exposures such as asbestos may increase the overall risk of OC.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Esophageal Neoplasms / etiology. Occupational Diseases / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18614460.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hazardous Substances
  • [Investigator] Vioquea J; Ponce E; Guillén M; Santibáñez M; Barber X; García de la Hera M; Hernández M; Bixquert M; Alonso J; Cervera V; Giner R; Ruiz J; Sanchos-Aldás C; Arenas J; Berenguer J; Sala T; Pascual S; Argüello L; Bustamante M; Sancho S; Herranz C; Aparicio J; Baixauli; Mir J; Sendrá P; Medina E; Tomé A; Ferrer L; Truyenque R; Olabarrieta L; Fabra R; Camps C; Vicent JM; Moreno-Osset E; Añón R; Ballester J; Alfonso V; Martínez-Abad; Blanes F; Molins C; Almenar D; Olmos S; Fenollosa; Benages-Martinez A; Peña-Aldea A; Pascual I; Conde G; Cervantes A; Azagra P; Lledó; Flor B; Martí V; Pérez-Mateos M; Casellas JA; Girona E; Aparicio JR; López M; Arroyo A; Camuñas F; de Anta J; Custardoy J; Martínez C; Gaspar E; Muñoz E; Carrato A; Gozálvez ML; Calpena R; Gassent; Pérez; Sillero CC; Medrano J; Mauri F; Corona M; Minguel J
  •  go-up   go-down


33. Fukazawa T, Maeda Y, Matsuoka J, Tanaka N, Tanaka H, Durbin ML, Naomoto Y: Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system. Int J Cancer; 2009 Oct 15;125(8):1975-84
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The success of cancer gene therapy depends on treatments where different types of tumors can be selectively targeted and destroyed without affecting normal cells and tissue.
  • Previously, we described a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells.
  • BID expression and apoptosis occurred in A549 pulmonary adenocarcinoma cells but little Bid expression or apoptosis occurred in MCF7 breast cancer cells or in normal human lung fibroblasts.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. BH3 Interacting Domain Death Agonist Protein / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoviridae / genetics. Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Caspases / metabolism. Cisplatin / administration & dosage. Colony-Forming Units Assay. Cytochromes c / metabolism. Dexamethasone / administration & dosage. Female. Fibroblasts / drug effects. Fibroblasts / metabolism. Flow Cytometry. Humans. Immunoblotting. Lung / drug effects. Lung / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19598260.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BH3 Interacting Domain Death Agonist Protein; 7S5I7G3JQL / Dexamethasone; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet; 2009 Jul 18;374(9685):239-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravesical treatment is used for carcinoma in situ and other high grade non-muscle-invasive tumours.
  • The standard of care for muscle-invasive disease is radical cystoprostatectomy, and several types of urinary diversions are offered to patients, with quality of life as an important consideration.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Transitional Cell / epidemiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Cystoscopy. Diagnosis, Differential. Hematuria / etiology. Humans. Molecular Biology. Neoadjuvant Therapy. Neoplasm Staging. Prostatectomy. Risk Factors. Sensitivity and Specificity. Survival Rate. United States / epidemiology. Urinary Diversion


35. Gourgiotis S, Ridolfini MP, Germanos S: Intraductal papillary mucinous neoplasms of the pancreas. Eur J Surg Oncol; 2007 Aug;33(6):678-84
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the site of involvement, IPMNs are classified into three types: main duct type, branch duct type, and combined type.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • The presence of large mural nodules increases the possibility of malignancy in all types.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Dilatation, Pathologic / pathology. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207960.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


36. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


37. Billis A: Prostatic atrophy. Clinicopathological significance. Int Braz J Urol; 2010 Jul-Aug;36(4):401-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic atrophy is a benign lesion that may mimic adenocarcinoma histologically and on imaging.
  • The latter may be partial, complete or combined.
  • Partial focal atrophy is the most frequent mimicker of adenocarcinoma on needle biopsies.
  • Combined lesions are frequent and partial atrophy may precede complete atrophy.
  • The several morphologic types of focal atrophy may represent a morphologic continuum and the hyperplastic (or postatrophic hyperplasia) subtype seems to be at the extreme end of this continuum.
  • Chronic inflammation associated to focal atrophy (proliferative inflammatory atrophy) has been linked to high-grade prostatic intraepithelial neoplasia and/or carcinoma.
  • The question whether inflammation directly produces tissue damage and atrophy or some other insult induces atrophy directly, with inflammation occurring secondarily, is still unresolved.
  • [MeSH-major] Carcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Prostatitis / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815946.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  •  go-up   go-down


38. Castillo A, Aguayo F, Koriyama C, Shuyama K, Akiba S, Herrera-Goepfert R, Carrascal E, Klinge G, Sánchez J, Eizuru Y: Human papillomavirus in lung carcinomas among three Latin American countries. Oncol Rep; 2006 Apr;15(4):883-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus in lung carcinomas among three Latin American countries.
  • The presence of human papillomavirus (HPV) genome in lung carcinomas has been reported worldwide but its frequency varies from country to country.
  • We examined HPV genome in 36 lung carcinomas, consisting of 14 squamous cell carcinomas, 13 adenocarcinomas, and 9 small cell carcinomas, collected from Colombia, Mexico and Peru.
  • PCR analysis using GP5+/GP6+ primers, combined with Southern blot hybridization, found the presence of HPV genome in 10 (28%) of 36 cases.
  • This percentage is similar to the value of 22% reported by Syrjänen, who conducted a meta-analysis of nearly 2500 lung carcinomas examined to date.
  • HPV-16 was more frequently found among female than male cases (P=0.008) but was not detected in any adenocarcinoma cases.
  • On the other hand, HPV-18 and HPV-33 were detected only among male cases.
  • The frequency of HPV-16 positive cases among all the HPV positive cases differed in the sexes (P=0.033) and differed in the three histological types (P=0.017).
  • The presence of HPV tended to be more frequent in well-differentiated tumors when squamous cell carcinomas and adenocarcinomas were combined.
  • Neither p16 nor p53 expression in carcinoma cells was related to the proportion of HPV-positive cases.
  • In conclusion, high-risk HPV DNA was detected in 28% of lung carcinomas.
  • The predisposition of HPV-16 to female cases and to non-adenomatous carcinomas warrants further investigation.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / virology. Aged. Blotting, Southern. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Colombia. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / chemistry. DNA, Viral / genetics. DNA, Viral / isolation & purification. Female. Genome, Viral. Genotype. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Humans. Immunohistochemistry. Male. Mexico. Middle Aged. Peru. Sequence Analysis, DNA. Sex Factors. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525675.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Ridolfini MP, Gourgiotis S, Alfieri S, Di Miceli D, Rotondi F, Limongelli F, Quero G, Larghi A, Cazzato MT, Martella N, Doglietto GB: [Presentation, treatment and prognosis of intraductal papillary mucinous neoplasm]. Ann Ital Chir; 2007 Jul-Aug;78(4):257-64
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IPMNs are classified into three types, according to the site of involvement: main duct type, branch duct type, and combined type.
  • Most branch type IPMNs are benign, while the other two types are frequently malignant.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990599.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 75
  •  go-up   go-down


40. Newkirk KM, Rohrbach BW: A retrospective study of eyelid tumors from 43 cats. Vet Pathol; 2009 Sep;46(5):916-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 12 squamous cell carcinomas (SCCs), 11 mast cell tumors (MCTs), 6 hemangiosarcomas (HSAs), 4 adenocarcinomas (ACAs), 3 peripheral nerve sheath tumors (PNSTs), 3 lymphomas, 3 apocrine hidrocystomas (AHCs), and 2 hemangiomas.
  • Cats with MCTs were significantly younger than cats with all other tumor types combined.
  • In contrast, cats with SCCs were significantly older than cats with other tumor types.
  • The HSAs and SCCs were significantly more likely than other tumors to occur in nonpigmented areas.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Animals. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / veterinary. Cats. Female. Hemangiosarcoma / epidemiology. Hemangiosarcoma / pathology. Hemangiosarcoma / veterinary. Hidrocystoma / epidemiology. Hidrocystoma / pathology. Hidrocystoma / veterinary. Immunohistochemistry / veterinary. Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma / veterinary. Male. Mastocytosis / epidemiology. Mastocytosis / pathology. Nerve Sheath Neoplasms / epidemiology. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / veterinary. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19429997.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, Zhao L, Huang S, Liu S, Cao G: Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res; 2010 Jul 15;16(14):3760-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of olfactomedin 1 protein was significantly higher in lung adenocarcinoma than in lung cancer of other histologic types and normal lung tissues.
  • Olfactomedin 1 may be a novel target of lung adenocarcinoma.
  • [MeSH-major] Antigens, Neoplasm / blood. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Antigen-Antibody Reactions. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cloning, Molecular. Humans. Immunohistochemistry. Peptides. Pulmonary Disease, Chronic Obstructive / blood. Pulmonary Disease, Chronic Obstructive / immunology. Regression Analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20501620.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Peptides
  •  go-up   go-down


42. Yang WL, Yan CQ, Zhang HG, Wang FJ, Ma YL: [Surgical treatment and prognosis of cancer of hepatic flexure of colon invading the duodenum in 65 patients]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):873-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To discuss surgical treatment of right colon carcinoma of hepatic flexure invading the duodenum.
  • METHODS: Sixty-five patients with right colon carcinoma of hepatic flexure invading the duodenum, treated in our department from 1987 to 2007, were included in this study.
  • All the cases were divided into three types (local invasion, regional invasion, and cancer with internal fistula) according to duodenal defect, including local invasion (< 2.0 cm), wide invasion (> 2.0 cm) and the presence of internal fistula.
  • 4 patients underwent pancreaticoduodenectomy combined with right hemicolectomy for colon cancer involving the pancreatic head.
  • Other patients were cured without postoperative complications.
  • [MeSH-major] Adenocarcinoma / surgery. Colon, Ascending / surgery. Colonic Neoplasms / surgery. Duodenum / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Colectomy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Quality of Life. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137356.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Rousseau MC, Parent ME, Siemiatycki J: Comparison of self-reported height and weight by cancer type among men from Montreal, Canada. Eur J Cancer Prev; 2005 Oct;14(5):431-8
MedlinePlus Health Information. consumer health - Body Weight.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among men there is epidemiological evidence for an association between obesity and increased risk of renal cell carcinoma, colon cancer and adenocarcinoma of the oesophagus.
  • The evidence for other cancer sites remains inconsistent.
  • We compared height, weight and body mass index (BMI) among individuals with 11 different cancer types (combined N=3016) and population-based controls (N=509).
  • Because of potential information bias and reverse causality bias, we focused on the comparisons among cancer types.
  • The lowest BMI values were observed among men with squamous cell carcinoma of the oesophagus, lung and stomach cancers.
  • The highest BMIs were reported by men with prostate and kidney cancers, and oesophageal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175048.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


44. Roa JC, Garcia P, Gomez J, Fernández W, Gaete F, Espinoza A, Lepetic A, Suarez E: HPV genotyping from invasive cervical cancer in Chile. Int J Gynaecol Obstet; 2009 May;105(2):150-3
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the prevalence rates of the different HPV types in cervical cancer lesions in Chile to facilitate the development of prophylactic human papillomavirus (HPV) vaccines effective for that country.
  • CONCLUSIONS: HPV types 16, 18, 31, and 45, alone or combined with other types, were observed in the biopsy samples of up to 80.5% of cervical cancer lesions.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249046.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


45. Feigenberg SJ, Hanlon AL, Langer C, Goldberg M, Nicolaou N, Millenson M, Coia LR, Lanciano R, Movsas B: A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol; 2007 Apr;2(4):287-92
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma had a 5-year overall survival of 28% versus 68% for all other cell types.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409799.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


46. Coban S, Ozkan H, Köklü S, Yüksel O, Koçkar MC, Akar T, Ormeci N: The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can J Gastroenterol; 2006 Sep;20(9):593-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To measure the serum levels of RCAS1 in patients with gastrointestinal (GI) tract cancers and compare them with other GI tract tumour markers.
  • Mean serum RCAS1 levels were not statistically significant among histopathological tumour types (P>0.05).
  • CONCLUSIONS: RCAS1 may be used and combined with CEA as a tumour marker in GI tract cancers.
  • [MeSH-minor] Adenocarcinoma / immunology. Adult. Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Squamous Cell / immunology. Case-Control Studies. Colonic Neoplasms / immunology. Esophageal Neoplasms / immunology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity. Stomach Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2003 Oct;56(10):764-8 [14514780.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1669-74 [14571813.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):679-85 [12861064.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):310-5 [12845666.001]
  • [Cites] Pancreas. 2003 Jan;26(1):49-55 [12499917.001]
  • [Cites] Oncology. 2003;64(1):83-9 [12457035.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):418-23 [11992411.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):101-5 [11809537.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1922-7 [11747335.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):446-51 [11466701.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):197-202 [11403925.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):91-6 [11391627.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):488-93 [11102892.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1891-4 [14534714.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):805-20 [8960894.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1501-9 [8608535.001]
  • [Cites] Dig Liver Dis. 2004 Sep;36(9):622-7 [15460847.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):259-67 [15254686.001]
  • [Cites] Int J Hematol. 2004 May;79(4):340-4 [15218962.001]
  • [Cites] Cancer Sci. 2004 Mar;95(3):260-5 [15016327.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):4967-71 [14981953.001]
  • [Cites] J Hepatol. 2003 Oct;39(4):559-63 [12971966.001]
  • (PMID = 17001401.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / EBAG9 protein, human
  • [Other-IDs] NLM/ PMC2659945
  •  go-up   go-down


47. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX, Retrospective International Survey and HPV Time Trends Study Group: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol; 2010 Nov;11(11):1048-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sequence analysis was done to characterise HPV-positive samples with unknown HPV types.
  • The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90-92).
  • HPV types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70-72) of invasive cervical cancer.
  • HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92-96) of cervical adenocarcinomas.
  • Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer.
  • Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively).
  • HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines.
  • Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / isolation & purification. Papillomaviridae / genetics. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology


48. Lee PN, Hamling J: The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviews. BMC Cancer; 2009;9:256
MedlinePlus Health Information. consumer health - Smokeless Tobacco.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Boffetta et al. claimed a significant 60-80% increase for oropharyngeal, oesophageal and pancreatic cancer, and a non-significant 20% increase for lung cancer, data for other cancers being "too sparse".
  • We found no association with stomach, bladder and all cancers combined, using data as extensive as that for oesophageal, pancreatic and lung cancer.
  • RESULTS: One major reason for the difference is our more consistent approach in choosing between study-specific never smoker and combined smoker/non-smoker estimates.
  • For pancreatic cancer, their review included significantly increased never smoker estimates in one study and combined smoker/non-smoker estimates in another, omitting a combined estimate in the first study and a never smoker estimate in the second showing no increase.
  • For oesophageal cancer, never smoker results from one study showing a marked increase for squamous cell carcinoma were included, but corresponding results for adenocarcinoma and combined smoker/non-smoker results for both cell types showing no increase were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] BMC Med. 2009;7:36 [19638245.001]
  • [Cites] J Natl Cancer Inst. 1969 Jun;42(6):1069-94 [5793187.001]
  • [Cites] Am J Epidemiol. 1970 May;91(5):486-99 [5438996.001]
  • [Cites] J Natl Cancer Inst. 1977 Mar;58(3):525-47 [557114.001]
  • [Cites] N Engl J Med. 1981 Mar 26;304(13):745-9 [7193288.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Head Neck Surg. 1986 Nov-Dec;9(2):104-10 [3623935.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3282-7 [3365707.001]
  • [Cites] J Natl Cancer Inst. 1988 Dec 21;80(20):1620-5 [3193480.001]
  • [Cites] J Clin Epidemiol. 1991;44(2):127-39 [1995774.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Oct;49(10):1044-7; discussion 1048-9 [1653824.001]
  • [Cites] J Clin Epidemiol. 1992 Mar;45(3):223-31 [1569419.001]
  • [Cites] Am J Epidemiol. 1992 Jun 1;135(11):1301-9 [1626547.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1369-75 [8339227.001]
  • [Cites] Cancer Causes Control. 1993 Sep;4(5):477-82 [8218880.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1137-44 [7721514.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jan;6(1):15-9 [8993792.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1367-75 [9529030.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):341-6 [9663593.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Br Med J. 1957 May 18;1(5028):1137-43 [13426561.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):992-5 [15645430.001]
  • [Cites] Cancer Causes Control. 2005 May;16(4):347-58 [15953977.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1107-15 [16184477.001]
  • [Cites] Acta Otolaryngol. 2005 Sep;125(9):991-8 [16193590.001]
  • [Cites] Cancer. 2007 Jun 15;109(12):2547-56 [17492688.001]
  • [Cites] Lancet. 2007 Jun 16;369(9578):2015-20 [17498797.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1095-9 [17973262.001]
  • [Cites] BMC Public Health. 2007;7:334 [18005437.001]
  • [Cites] Stat Med. 2008 Mar 30;27(7):954-70 [17676579.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):168-73 [18412245.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):667-75 [18598931.001]
  • [Cites] BMC Cancer. 2008;8:356 [19046421.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):55-8 [14744733.001]
  • (PMID = 19638246.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3087330
  •  go-up   go-down






Advertisement